|
|||||
|
|
CD99 expression is strongly associated with clinical outcome in children with B-cell precursor acute lymphoblastic leukaemia |
|
| Authors: | Dongfeng Chen Alessandro Camponeschi Qingqing Wu Natalija Gerasimcik Huiqi Li Xue Shen Yujie Tan Helene Sjögren Jessica Nordlund Gudmar Lönnerholm Jonas Abrahamsson Linda Fogelstrand Inga-Lill Mårtensson |
| Affiliation: | 1. Department of Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden;2. The Central Laboratory, The Affiliated Hospital of Guizhou Medical University, Guiyang, China;3. Department of Occupational and Environmental Medicine, University of Gothenburg, Gothenburg, Sweden;4. Department of Clinical Chemistry, Sahlgrenska University Hospital, Gothenburg, Sweden;5. Department of Medical Sciences, Molecular Medicine and Science for Life Laboratory, Uppsala University, Uppsala, Sweden;6. Department of Women and Children's health, Uppsala University, Uppsala, Sweden;7. Department of Paediatrics, Institution of Clinical Sciences, Sahlgrenska University Hospital, Gothenburg, Sweden;8. Department of Clinical Chemistry, Sahlgrenska University Hospital, Gothenburg, Sweden Department of Clinical Chemistry and Transfusion Medicine, University of Gothenburg, Gothenburg, Sweden |
| Abstract: | Our study aimed to determine the expression pattern and clinical relevance of CD99 in paediatric B-cell precursor acute lymphoblastic leukaemia (BCP-ALL). Our findings demonstrate that high expression levels of CD99 are mainly found in high-risk BCP-ALL, e.g. BCR-ABL1 and CRLF2Re/Hi, and that high CD99 mRNA levels are strongly associated with a high frequency of relapse, high proportion of positive for minimal residual disease at day 29 and poor overall survival in paediatric cohorts, which indicate that CD99 is a potential biomarker for BCP-ALL. |
| Keywords: | BCP-ALL CD99 biomarker acute leukaemia prognosis |